Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevasiranib Maintenance Therapy in Wet AMD
NCT00499590Phase 3Terminated
- Sponsor
- OPKO Health
- Start
- Aug 2007
- Primary completion
- Mar 2009
- Modality
- Antisense DNA, Conjugated siRNA, MicroRNA (miRNA)
- Countries
- 2
01
Overview
A Phase 3 trial of bevasiranib in exudative age-related macular degeneration, sponsored by OPKO Health. Started Aug 2007; status: terminated.
02
Drugs
bevasiranib
03
Conditions
exudative age-related macular degeneration
Beyond the preview
Go deeper on NCT00499590.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00499590.